University of Zurich
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 1833-04-29
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.uzh.ch
Clinical Trials
1.0k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (644 trials with phase data)• Click on a phase to view related trials
Effects of Cerebrospinal Fluid Drainage on Cerebral Hemodynamics
- Conditions
- Acute Ischemic Stroke
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 30
- Registration Number
- NCT07056907
- Locations
- 🇨🇭
University Hospital Zurich, Zurich, Switzerland
Feasibility of MR-Informed Adaptive Marker-less SBRT in Patients With Bilateral Hip Prostheses Undergoing SBRT for Localized Prostate Cancer
- Conditions
- Localized Prostate Adenocarcinoma
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 13
- Registration Number
- NCT07042256
Robotic-assisted Bronchoscopy Under Moderate Sedation With Propofol
- Conditions
- Lung LesionsRobotic Assisted BronchoscopyPropofolBronchoscopyBronchoscopy Biopsy
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 30
- Registration Number
- NCT07006311
Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma
- Conditions
- Allergic RhinitisAllergic Asthma
- Interventions
- Drug: ALUTARD SQ® Felis domesticus
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 36
- Registration Number
- NCT06960382
- Locations
- 🇨🇭
University Hospital Zurich, Zurich, Switzerland
Optic Nerve Sonography to Monitor Intracranial Pressure After Ischemic sTrokE - The ONSITE Study
- Conditions
- Malignant Media InfarctionStrokeIntracranial Hypertension
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 107
- Registration Number
- NCT06939114
- Locations
- 🇨🇭
University Hospital Zurich, Zurich, Switzerland
- Prev
- 1
- 2
- 3
- 4
- 5
- 202
- Next
News
Arcturus Therapeutics to Present Phase 2 Data for ARCT-810 mRNA Therapy in Rare Genetic Disorder
Arcturus Therapeutics will host a virtual presentation on June 30, 2025, featuring Phase 2 interim data for ARCT-810, an investigational mRNA therapeutic for ornithine transcarbamylase deficiency.
Phase 1/2 KEYMAKER-U02 Trial: Pembrolizumab Shows Manageable Safety Profile in Stage IIIB-D Melanoma
Neoadjuvant pembrolizumab, alone or combined with vibostolimab or gebasaxturev, demonstrated a manageable safety profile in stage IIIB-D melanoma patients, with 95% experiencing at least one adverse event.